Xin Lang Cai Jing·2026-01-13 07:36Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise established in 1998, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development and commercialization, benefiting from the depreciation of the RMB [2][3]. Company Overview - Haiprui is headquartered in Shenzhen, China, and was listed on May 6, 2010. Its main business includes the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The revenue composition of Haiprui is as follows: formulations 63.06%, CDMO 18.59%, heparin sodium and low molecular weight heparin raw materials 16.05%, and others 2.30% [7]. - As of September 30, 2025, Haiprui achieved a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The overseas revenue proportion of Haiprui is 93.04%, benefiting from the depreciation of the RMB [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed in the last three years [8]. Market Activity - On January 13, Haiprui's stock rose by 0.73%, with a trading volume of 78.39 million yuan and a turnover rate of 0.50%, bringing the total market capitalization to 18.238 billion yuan [1]. - The main net inflow of funds today was 2.6446 million yuan, accounting for 0.03%, with no significant trend in the main force observed [4][5].